Aptose Biosciences Inc.
APTOF
$1.71
$0.031.91%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.55% | 19.66% | 23.57% | -6.58% | -12.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 239.64% | -29.46% | -5.77% | -44.05% | -81.97% |
| Operating Income | -239.64% | 29.46% | 5.77% | 44.05% | 81.97% |
| Income Before Tax | -389.53% | 26.32% | 2.88% | 42.50% | 86.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -389.53% | 26.32% | 2.88% | 42.50% | 86.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -389.53% | 26.32% | 2.88% | 42.50% | 86.74% |
| EBIT | -239.64% | 29.46% | 5.77% | 44.05% | 81.97% |
| EBITDA | -240.08% | 29.58% | 5.72% | 43.99% | 81.97% |
| EPS Basic | -127.21% | 82.29% | 78.75% | 88.16% | 97.07% |
| Normalized Basic EPS | -127.21% | 82.29% | 78.75% | 88.16% | 97.07% |
| EPS Diluted | -127.21% | 82.29% | 78.75% | 88.16% | 97.07% |
| Normalized Diluted EPS | -127.21% | 82.29% | 78.75% | 88.16% | 97.07% |
| Average Basic Shares Outstanding | 115.46% | 315.97% | 357.01% | 385.68% | 353.23% |
| Average Diluted Shares Outstanding | 115.46% | 315.97% | 357.01% | 385.68% | 353.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |